Exenatide
$74.99 – $119.99Price range: $74.99 through $119.99
The first FDA-approved GLP-1 agonist derived from Gila monster venom, available as twice-daily and once-weekly formulations.
Molecular & analytical data
Verified chemistry and third-party reference identifiers for this compound.

Reconstitution calculator
Concentration, volume per draw, and the graduation it measures to. Open the full bench calculator with this vial loaded →
—
A U-100 insulin syringe reads 100 units per 1 mL. Figures describe the contents of a vial for laboratory handling reference only and are not dosing guidance.
Quality & verification
Every batch is characterised before release and ships with documentation.
Storage & handling
Keep the peptide stable from delivery through reconstitution.
Refrigerate at 2-8°C.
Exenatide was the first GLP-1 receptor agonist approved by the FDA (2005). It is a synthetic version of exendin-4, a hormone originally discovered in the saliva of the Gila monster lizard. Available as Byetta (twice-daily injection) and Bydureon (once-weekly extended-release injection). While newer GLP-1 agents have surpassed it in convenience and efficacy, exenatide played a pioneering role in establishing the GLP-1 drug class and remains in clinical use.
Certificates of Analysis
Every batch of this peptide is tested before release. Find the batch number printed on your vial and verify or download its certificate.
| Batch # | Issued | Purity | Certificate |
|---|---|---|---|
| NHV26-P5340 COA-AKMP-0N1Z-F | 04 Aug 2026 | 98.61 % HPLC | Verify at IRZC ↗ |
“Verify at IRZC” opens the laboratory’s own record for that certificate, on their site. Looking for an older batch we haven’t published? Email [email protected] with the batch number from your vial — we keep all certificates for 7 years.
The information below summarises published preclinical and clinical research for scientific reference. NHOV products are sold strictly for laboratory research use only. Nothing here is medical advice, a recommendation, or an instruction for use in humans or animals.
Mechanism of action
GLP-1 receptor agonist (exendin-4 backbone), glucose-dependent insulin stimulation, glucagon suppression, delayed gastric emptying, appetite reduction.
Primary uses / indications
Type 2 diabetes management
Typical dosage (reported)
Byetta: 5-10 mcg twice daily before meals. Bydureon: 2 mg once weekly.
Cycle duration (reported)
Long-term ongoing treatment
Administration route
Subcutaneous injection (twice daily or once weekly depending on formulation)
Side effects (reported)
Nausea, vomiting, diarrhea, dizziness, headache, jittery feeling, injection site reactions (nodules with Bydureon).
Contraindications
MTC/MEN 2 (Bydureon), severe renal impairment, personal history of pancreatitis, pregnancy
Drug interactions
Potentiates hypoglycemia with sulfonylureas. Affects gastric emptying and oral drug absorption.
Identity
| Full name / brand names | Exenatide (Byetta, Bydureon) |
|---|---|
| Category | GLP-1 Receptor Agonists |
| Subcategory | Exendin-4 Based GLP-1 Agonist |
| Origin / source | Synthetic; based on exendin-4 from Gila monster saliva. Manufactured by AstraZeneca. |
| Year discovered | FDA approved 2005 (Byetta) |
Chemistry
| Amino acid sequence | 39-amino-acid peptide based on exendin-4 from Heloderma suspectum |
|---|---|
| Molecular formula | C184H282N50O60S |
| Molecular weight | 4186.63 g/mol |
| CAS number | 141758-74-9 |
| PubChem CID | CID 45588096 ↗ |
| UniProt ID | P26349 (Exendin-4, Heloderma suspectum) |
| Purity standard | ≥98% |
Pharmacokinetics
| Half-life | ~2.4 hours (immediate release); ~2 weeks (extended release microspheres) |
|---|---|
| Bioavailability | Subcutaneous: moderate |
Regulatory & research status
| FDA status | FDA-Approved. Byetta (2005), Bydureon (2012) for type 2 diabetes. |
|---|---|
| Prescription required | Yes — prescription required |
| Research status | FDA-approved; well-established drug with long-term safety data. |
| Clinical trials | NCT00308139 (DURATION-1); FDA-approved (Byetta 2005, Bydureon 2012) |
References
Holst JJ, "The physiology of glucagon-like peptide 1", Physiological Reviews, 2007, DOI: 10.1152/physrev.00034.2006; Drucker DJ et al., "Exenatide once weekly versus twice daily for the treatment of type 2 diabetes", Lancet, 2008, DOI: 10.1016/S0140-6736(08)61206-4
Frequently asked questions
What is Exenatide?
How does Exenatide work?
What Exenatide dosage is used in research?
What is the half-life of Exenatide?
How should Exenatide be stored and reconstituted?
What purity is NHOV's Exenatide?
Is Exenatide approved for human use?
Related products
Pre-order 
Tirzepatide
Dual GIP and GLP-1 receptor agonist studied for incretin metabolic research.
$30.99 – $189.99Price range: $30.99 through $189.99Orforglipron
Oral non-peptide small-molecule partial agonist at the GLP-1 receptor.
$74.99 – $119.99Price range: $74.99 through $119.99Retatrutide
Investigational triple agonist of GLP-1, GIP, and glucagon receptors.
$48.99 – $164.99Price range: $48.99 through $164.99Cagrilintide
Long-acting amylin and calcitonin receptor agonist studied in metabolic research.
$64.99 – $108.99Price range: $64.99 through $108.99Liraglutide
GLP-1 receptor agonist studied for glucose-dependent insulin secretion.
$83.99 – $134.99Price range: $83.99 through $134.99Dulaglutide
GLP-1 receptor agonist built as a fused peptide-Fc protein; metabolic research.
$74.99 – $119.99Price range: $74.99 through $119.99Mazdutide
33-amino-acid oxyntomodulin analog; dual GLP-1/glucagon receptor agonist.
$59.99 – $79.99Price range: $59.99 through $79.99Survodutide
29-amino-acid GLP-1/glucagon dual agonist studied in metabolic liver research.
$56.99 – $109.99Price range: $56.99 through $109.99











Reviews
Clear filtersThere are no reviews yet.